Revision of Viable Environmental Monitoring in a Development Pilot Plant Based on Quality Risk Assessment: A Case Study

Reference

1. 1.↵
   1. Mohammed-Ziegler I.,
   2. Medgyesi I.

   Increased Importance of Documented Development Stage in Process Validation. Saud. Pharm. J. 2012, 20 (3), 283–285.

   OpenUrl
2. 2.↵
   1. Kieffer R. G.

   The Changing Role of Quality Assurance in the Pharmaceutical Industry. PDA J. Pharm. Sci. Technol. 2014, 68 (4), 313–319.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   U.S. Food and Drug Administration (FDA), Guidance for Industry Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice, Rockville, MD, September 2004.
4. 4.↵
   FDA. Pharmaceutical GMPs for the 21st Century—A Risk Based Approach, Rockville, MS, September 2004.
5. 5.↵
   European Medicines Agency (EMA). Eudralex, Volume 4, EU GMP, Annex 1. Manufacture of Sterile Medicinal Products, Section 8, Brussels, 25 November 2008.
6. 6.↵
   International Conference on Harmonization (ICH). Q9 Quality Risk Management, Harmonised Tripartite Guideline, 2009.
7. 7.↵
   Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Guide to Good Manufacturing Practice for Medicinal Products—PE 009-12 (Annexes), Annex 1. Manufacture of sterile medicinal products, Geneva, 1 October 2015.
8. 8.↵
   World Health Organization. WHO Technical Report Series, No. 961, Annex 6. WHO Good Manufacturing Practices for Sterile Pharmaceutical Products, 2011.
9. 9.↵
   Agencia Nacional de Vigilância Sanitária (ANVISA). Guia da Qualidade para Sistemas de Tratamento de Ar e Monitoramento Ambiental na Indústria Farmaceutica (Guide for Quality of Air-Treatment Systems and Environmental Monitoring in the Pharmaceutical Industry), Brazil, 08 May 2013.
10. 10.↵
    EMA Concept Paper on the Revision of Annex 1 of the Guidelines on Good Manufacturing Practice—Manufacture of Sterile Medicinal Products, 2 February 2015.
11. 11.↵
    FDA 21 Code of Federal Regulations (CFR) Part 211 Current Good Manufacturing Practice for Finished Pharmaceuticals, 01 April 2016.
12. 12.↵
    1. Sandle T.

    Environmental Monitoring Risk Assessment. J. GXP Compliance 2006, 10 (2), 54–73.

    OpenUrl
13. 13.↵
    1. Lorcheim P.,
    2. Hughes M.

    Environmental Monitoring and Decontamination of Pharmaceutical Production Facilities. Pharmaceutical Engineering 2012, 32 (6), 74–79.

    OpenUrl
14. 14.↵
    1. Saghee M. R.,
    2. Sandle T.,
    3. Tidswell E. C.

    1. Sandle T.

    Risk Management in Pharmaceutical Microbiology. In Microbiology and Sterility Assurance in Pharmaceuticals and Medical Devices, Saghee M. R., Sandle T., Tidswell E. C., Eds.; Business Horizons: New Delhi, 2010.
15. 15.↵
    1. Sandle T.

    Application of Quality Risk management To Set Viable Environmental Monitoring Frequencies in Biotechnology Processing and Support Areas. PDA J. Pharm. Sci. Technol. 2012, 66 (6), 560–579.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Moldenhauer J.

    Environmental Monitoring: A Comprehensive Handbook; DHI/PDA: Bethesda, MD; Vol. I, 2005.
17. 17.↵
    1. Sutton S.

    The Environmental Monitoring Program in a GMP Environment. J. GXP Compliance 2010, 14 (3), 22–30.

    OpenUrl
18. 18.↵
    1. Akers J.,
    2. Agalloco J.

    The Simplified Akers-Agalloco Method for Aseptic Processing Risk Analysis. Pharm. Technol. 2006, 30 (7), 60–72.

    OpenUrl
19. 19.↵
    1. Laenge R.,
    2. Steger-Hartmann T.,
    3. Schweinfurth H.

    The Environmental Risk Assessment of Human Pharmaceuticals in the Overall EU Regulatory Affairs Process. Regul. Toxicol. Pharmacol. 2006, 45 (3), 223–228.

    OpenUrlPubMed
20. 20.↵
    1. Madigan M. T.,
    2. Martinko J. M.

    Brock Biology of Microbiology, 11th ed.; Pearson Prentice Hall: Boston, MA, 2006; p 136.
21. 21.
    1. Sandle T.,
    2. Skinner K.

    Study of Psychrophilic and Psychrotolerant Microorganisms Isolated in Cold Rooms Used for Pharmaceutical Processing. J. Appl. Microbiol. 2013, 114 (4), 1166–1174.

    OpenUrl
22. 22.↵
    1. O'Donnell K.

    Strategies for Addressing the Problems of Subjectivity and Uncertainty in Quality Risk Management Exercises: Part I—The Role of Human Heuristics. J. Valid. Technol. 2010, 16 (3) 23–31.

    OpenUrl